Current Status of Research on Anti-osteoporotic Drug Treatment and Compliance in Patients with Osteoporotic Fractures
DOI:
https://doi.org/10.53469/jcmp.2024.06(06).02Keywords:
Osteoporotic fractures, Medication, Medication adherenceAbstract
Osteoporotic Fracture (OPF), also known as fragility fracture, is a low-energy, non-violent fracture that commonly occurs in the elderly. Such fractures mostly occur in the thoracolumbar vertebral body, hip, distal radius and other parts, and are the main factors that cause osteoporosis patients to be hospitalized for diagnosis and treatment. Secondary fractures are prone to occur after fractures, and anti-osteoporotic treatment can effectively prevent further fractures in patients with osteoporotic fractures. Due to factors such as patients and their families’ insufficient understanding of the necessity of anti-osteoporosis drug treatment after fragility fractures, insufficient awareness of the risk of re-fracture, lack of follow-up management of drug compliance after treatment, and untimely monitoring of anti-osteoporosis efficacy, etc. The treatment initiation rate and medication compliance of anti-osteoporosis drugs in patients with osteoporotic fractures are low. This article systematically reviews the incidence and disease burden of osteoporotic fractures, the understanding of diagnosis, treatment and management of osteoporotic fractures, the status of anti-osteoporotic drug treatment and compliance, and efficacy monitoring of patients after osteoporotic fractures. Provide a reference for establishing effective medication compliance management for OPF patients.
References
Chinese Society of Orthopaedics. Guidelines for the diagnosis and treatment of osteoporotic fractures (2022 edition) [J]. Chinese Journal of Orthopaedics, 2022, 42(22): 1473-1491.
Kim SJ, Park HS, Lee DW, et al. Short-term daily teriparatide improves postoperative functional outcome and fracture healing in unstable intertrochanteric fractures. [J]. INJURY, 2019, 50(7):1364-1370.
Briggs AM, Sun W, Miller LJ, et al. Hospitalisations, admission costs and re-fracture risk related to osteoporosis in Western Australia are substantial: a 10-year review. [J]. AUST NZ J PUBL HEAL, 2015, 39(6):557-562.
Ma X, Xia H, Wang J, et al. Re-fracture and correlated risk factors in patients with osteoporotic vertebral fractures. [J]. J BONE MINER METAB, 2019, 37(4):722-728.
OJ, AK J. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. [J]. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2006, 17(12).
JB, E Å K, AS, et al. Risk of imminent fracture following a previous fracture in a Swedish database study. [J]. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2019, 30(3).
National Bureau of Statistics. Bulletin of the Seventh National Census (No. 5) 2021-5-11. [EB/OL]. https://www.stats.gov.cn/xxgk/sjfb/zxfb2020/202105 /t20210511_1817200.html.
Chen X, Hu Y, Geng Z, et al. The “Three in One “Bone Repair Strategy for Osteoporotic Fractures. [Z]. 2022: 13, 910602.
Yang Zhaoxu, Xing Dong, Zhang Long, et al. Epidemiological investigation on re-fractures after osteoporotic fracture surgery in the elderly [J]. Chinese Journal of Bone and Joint Injury, 2022, 37(03): 277-279.
Wei Gengsheng, Wu Jingliang, Wu Lei. Analysis of drug initiation rate and compliance in elderly patients with osteoporotic hip fracture [J]. Journal of Clinical Orthopedics, 2017, 20(02): 175-178.
Zhang Lili, Jiang Jinheng, Lu Houchen. Chinese Guidelines for Standardized Anti-Osteoporosis Treatment after Fragility Fracture Surgery (2021) [J]. Chinese Journal of Orthopedics and Traumatology, 2021, 23(02):93-101.
Oh HS, Kim SK, Seo H Y. Characteristics of Osteoporosis & Osteoporotic Fractures in Korea Based on Health Insurance Review and Assessment (HIRA) Database: 2009-2017. [J]. Healthcare (Basel), 2021, 9(3).
Chandran M, Lau TC, Gagnon-Arpin I, et al. The health and economic burden of osteoporotic fractures in Singapore and the potential impact of increasing treatment rates through more pharmacological options. [Z]. 2019: 14, 114.
Cui L, Jackson M, Wessler Z, et al. Estimating the future clinical and economic benefits of improving osteoporosis diagnosis and treatment among women in China: a simulation projection model from 2020 to 2040[J]. Arch Osteoporos, 2021, 16(1):118.
Yu Shufang, Guo Junzhe, Wu Bin, et al. Analysis of questionnaire survey on osteoporosis diagnosis and treatment among orthopedic surgeons in tertiary hospitals [J]. Chinese Journal of Joint Surgery (Electronic Edition), 2013, 7(06):870-873.
Lu J, Ren Z, Liu X, et al. Osteoporotic Fracture Guidelines and Medical Education Related to the Clinical Practices: A Nationwide Survey in China. [J]. ORTHOP SURG, 2019, 11(4):569-577.
International Osteoporosis Foundation. Fight The fracture-IOF survey 2017[EB/OL]. https://www.osteoporosis.foundation/educational-hub/material/surveys.
Chen YJ, Kung PT, Chou WY, et al. Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan. [J]. OSTEOPOROSIS INT, 2020, 31(8):1555-1563.
Olarte CM, López AM, Tihanyi Feldman J, et al. Impact of a Secondary Prevention Program for Fragility Fractures at the Orthogeriatric Clinical Care Center at the Fundación Santa Fe de Bogotá, 2014-2020. [J]. GERIATR ORTHOP SURG, 2022, 13:1771140890.
Malle O, Borgstroem F, Fahrleitner-Pammer A, et al. Mind the gap: Incidence of osteoporosis treatment after an osteoporotic fracture - results of the Austrian branch of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS). [Z]. 2021: 142, 115071.
Ahn SH, Park SM, Park SY, et al. Osteoporosis and Osteoporotic Fracture Fact Sheet in Korea. [J]. J Bone Metab, 2020, 27(4):281-290.
Gillespie CW, Morin P E. Osteoporosis-Related Health Services Utilization Following First Hip Fracture Among a Cohort of Privately-Insured Women in the United States, 2008-2014: An Observational Study. [J]. J BONE MINER RES, 2017, 32(5):1052-1061.
Wang X, Li C, He Y, et al. Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010-2016 in Fujian, China. [J]. ARCH OSTEOPOROS, 2020, 15(1):134.
Xu Hao, Wang Peiwen, Li Yizhong, et al. The impact of bone density testing on the diagnosis and treatment rate of osteoporosis in patients with fragility hip fracture [J]. Chinese Journal of Gerontology, 2017, 36(07):784-787.
Tang Jinye. Retrospective study on the influencing factors of osteoporotic fractures and secondary fractures[D]. Yangzhou University, 2022.
Wei Fei, Yao Jing, Guo Yangdan, et al. Application of the “1+2+X” collaborative service model led by specialist nurses in the rehabilitation care of patients with osteoporotic vertebral compression fractures[J]. Nursing Research, 2021, 35(16): 2998-3000.
Huang He, Xiong Zhipeng, Liu Hui, et al. Establishment of a risk prediction model for recurrent fractures after vertebroplasty in patients with osteoporotic vertebral compression fractures[J]. Laboratory Medicine and Clinic, 2023, 20(24): 3672-3675.
Williamson J, Michaleff Z, Schneuer F, et al. An 11-year longitudinal analysis of refracture rates and public hospital service utilisation in Australia's most populous state. [J]. ARCH OSTEOPOROS, 2022, 17(1):76.
Zhang Zhenlin, Xia Weibo, Wang Chun, et al. Guiding principles for community diagnosis and treatment of primary osteoporosis [J]. Chinese Journal of Osteoporosis and Bone Mineral Diseases, 2019, 12(01):1-10.
Bone Metabolism Expert Group Chinese Journal of Osteoporosis, Zhang Mengmeng, Ma Qianqian, et al. Expert consensus on the clinical application of bone metabolism biochemical indicators (2023 revised edition) [J]. Chinese Journal of Osteoporosis, 2023, 29(04):469 -476.
Lee J, Vasikaran S. Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. [Z]. 2012: 32, 105-112.
Zhang Mengmeng. Life, bones, and vitamin D_3[J]. Chinese Journal of Osteoporosis, 2016, 22(11): 1496-1500.
Kong Dece, Yang Tieyi, Shao Jin, et al. Study on the relationship between 25(OH)D_3 and bone density and bone metabolism indicators in postmenopausal women aged 50-60 years old with fractures [J]. Chinese Journal of Osteoporosis, 2017, 23(02):191-196.
Zhang Ling, Cao Genyuan. Correlation between bone metabolism markers, blood lipid levels and primary osteoporosis[J]. Journal of Integrated Traditional Chinese and Western Medicine for Cardiovascular and Cerebrovascular Diseases, 2017, 15(19): 2510-2512.
Krege JH, Lane NE, Harris JM, et al. PINP as a biological response marker during teriparatide treatment for osteoporosis[J]. Osteoporos Int, 2014, 25(9):2159-2171.
Zhao J, Xia W, Nie M, et al. The levels of bone turnover markers in Chinese postmenopausal women: Peking Vertebral Fracture study[J]. Menopause, 2011, 18(11):1237-1243.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Xiaozhen Lin, Yiji Li, Limei Wang, Qiujiao Liao
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
